Core Insights - Renhe Yikang Group has obtained approval for the first generic version of the antibiotic drug, Saline Anlotinib Tablets, which is a significant milestone in the Chinese pharmaceutical market [4][6] - The company has also received approval for Palivizumab Sodium Injection, marking it as the second domestic company to produce this flu treatment [9][10] Group 1: Saline Anlotinib Tablets - Saline Anlotinib Tablets are indicated for treating chronic bronchitis acute exacerbations caused by Klebsiella pneumoniae and acute pyelonephritis and cystitis caused by Escherichia coli [4] - The drug is recognized as China's first innovative quinolone antibiotic with complete independent intellectual property rights and is included in national key new products [4] - Sales of Saline Anlotinib Tablets are projected to exceed 20 million yuan in 2024 across all terminal hospitals [4] Group 2: Palivizumab Sodium Injection - Palivizumab Sodium Injection is a new antiviral drug effective against both influenza A and B types, and it is the first intravenous neuraminidase inhibitor in China [9] - The drug achieved sales exceeding 1 billion yuan in 2024, with a year-on-year growth of 2.44%, and sales in the first half of 2025 are expected to surpass 600 million yuan [9] - Renhe Yikang has become the second domestic company to receive approval for this drug, following Qidu Pharmaceutical's approval in July 2025 [10][13] Group 3: Company Achievements - Renhe Yikang has received approval for over 70 drug varieties, with 15 of them being the first to pass the evaluation [13] - In the current year, the company has secured 19 drug approvals, with Saline Anlotinib Tablets being the only first generic approved [13]